Which mechanism of action is unique to ezetimibe among the lipid-lowering agents?

Explanation

## Ezetimibe: Unique Mechanism of Action **Key Point:** Ezetimibe is the only lipid-lowering drug that selectively inhibits cholesterol absorption in the small intestine by blocking the NPC1L1 (Niemann-Pick C1-Like 1) transporter on the intestinal brush border. ### Mechanism of Action Ezetimibe acts at the **intestinal epithelial level**, not the liver. It prevents the uptake of dietary and biliary cholesterol from the intestinal lumen, reducing cholesterol bioavailability and forcing the liver to upregulate LDL receptors to compensate for reduced hepatic cholesterol content. ### Comparison of Lipid-Lowering Drug Mechanisms | Drug Class | Primary Site | Mechanism | Effect on Cholesterol | |-----------|--------------|-----------|----------------------| | **Ezetimibe** | **Intestine** | **NPC1L1 transporter inhibition** | **↓ Absorption** | | Statins | Liver | HMG-CoA reductase inhibition | ↓ Synthesis | | Fibrates | Liver (PPAR-α) | PPAR-α activation | ↓ VLDL, ↑ HDL | | PCSK9 inhibitors | Liver (surface) | PCSK9 degradation inhibition | ↑ LDL receptor | | Bile acid sequestrants | Intestine | Cholesterol-rich bile acid binding | ↓ Reabsorption | **High-Yield:** Ezetimibe reduces LDL cholesterol by ~18–20% as monotherapy and is often combined with statins for additive effect (reduces LDL by additional 15–20% when added to statin). **Clinical Pearl:** Ezetimibe does NOT inhibit the synthesis of cholesterol; it prevents its absorption. This distinction is critical because patients with homozygous familial hypercholesterolemia (HoFH) who have defective LDL receptors still benefit from ezetimibe because intestinal absorption is independent of LDL receptor function.